Table 1.
Patient baseline characteristics (intent‐to‐treat population)
| Characteristic | N = 26 |
|---|---|
| Age, median (range), years | 75 (60–85) |
| Age distribution, n (%) | |
| ≤75 years | 14 (53.8) |
| >75 years | 12 (46.2) |
| <65 years | 2 (7.7) |
| ≥65 years | 24 (92.3) |
| Sex, n (%) | |
| Male | 13 (50.0) |
| Female | 13 (50.0) |
| ECOG performance status score, n (%) | |
| 0 | 13 (50.0) |
| 1 | 7 (26.9) |
| 2 | 6 (23.1) |
| International Staging System stage, n (%) | |
| I | 7 (26.9) |
| II | 14 (53.8) |
| III | 5 (19.2) |
| Creatinine clearance, n (%) | |
| ≥60 mL/min | 10 (38.5) |
| ≥30 to <60 mL/min | 14 (53.8) |
| <30 mL/min | 2 (7.7) |
| Albumin level, n (%) | |
| ≤3.5 g/dL | 20 (76.9) |
| >3.5 g/dL | 6 (23.1) |
| β2‐microglobulin level, n (%) | |
| ≤5.5 mg/L | 21 (80.8) |
| >5.5 mg/L | 5 (19.2) |
| Multiple myeloma subtype, n (%) | |
| IgG | 18 (69.2) |
| IgA | 6 (23.1) |
| Bence–Jones protein | 2 (7.7) |
ECOG, Eastern Cooperative Oncology Group; Ig, immunoglobulin.